Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovata Biomed in Japanese drug delivery deal:

This article was originally published in Clinica

Executive Summary

Innovata Biomed (IB), the respiratory drug delivery subsidiary of Warrington, UK-based ML Laboratories, has signed an agreement with Japanese healthcare company Otsuka Pharmaceutical Co. Under the terms of the agreement, the Tokyo-based company has been given an exclusive licence to market its asthma treatment product, Meptin, in IB's "Clickhaler" dry powder inhaler in Japan and Spain. In return, IB will receive milestone payments and will supply the inhalers to Otsuka. "We strongly believe that this combinations will provide asthma patients with the most reliable, easy-to-use solution," said Otsuka's operations officer Masuhiro Yoshitake. Paul Bellington, managing director of St. Albans-based IB, added: "Today's announcement supports Innovata Biomed's position as one of the leading independent providers of respiratory drug delivery technologies to the pharmaceuticals industry."

You may also be interested in...



Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel